Investor Presentaiton

Farletuzumab ecteribulin (FZEC) 1: Novel folate receptor alpha (FRA) ADC Overview . ⚫ FRa is a folate-binding protein that has limited expression on normal tissues and is overexpressed in malignant cells² MOA: Target delivery of differentiated payload, eribulin Tumour microenvironment FZEC binds to FRa on the surface of tumor cells, is internalized and cleaved to release the payload, eribulin - Eribulin inhibits microtubule growth resulting in cell death FZEC may potentially target tumors with heterogenous FRa expression through bystander effect of eribulin on nearby FRa-negative cells Development plan PoC trials ongoing in NSQ NSCLC, ovarian & endometrial cancers • In dose expansion to optimize the therapeutic index with data anticipated in 2024 FZEC FRa 2. Endocytosis 1. FZEC binds to FRO of FZEC 3. Lysosomal degradation, cleavage of linker and release of eribulin FRa-positive cancer cell 6. Released eribulin has bystander effects 4. Eribulin inhibits microtubule growth 5. Mitotic arrest leads to apopototic cell death and immunogenic cell death High addressable population based on range of FR expression Ill Bristol Myers Squibb™ 1. In partnership with Eisai; 2. Level of overexpression may vary depending on tumor type Not for Product Promotional Use 150

View entire presentation